Moderna appoints Ester Banque chief commercial officer, expands Stephen Hoge role

Moderna

Moderna

MRNA

0.00
  • Moderna revamped its operating model as it prepares for up to three potential product launches in 2027-2028.
  • President Stephen Hoge took expanded operational oversight across R&D, manufacturing, commercial for infectious disease, intismeran, rare disease franchises.
  • Ester Banque joined as chief commercial officer effective June 15, 2026, reporting to CEO Stéphane Bancel.
  • Banque was EVP, president of U.S. operations at Zoetis; previously led BMS U.S. hematology and cell therapy; spent 25 years at Novartis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606160730ACCESSWRNAPR_____1177936) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.